These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31577946)

  • 21. Critical roles of a dendritic cell subset expressing a chemokine receptor, XCR1.
    Yamazaki C; Sugiyama M; Ohta T; Hemmi H; Hamada E; Sasaki I; Fukuda Y; Yano T; Nobuoka M; Hirashima T; Iizuka A; Sato K; Tanaka T; Hoshino K; Kaisho T
    J Immunol; 2013 Jun; 190(12):6071-82. PubMed ID: 23670193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Type I Interferon Signaling Is Required for CpG-Oligodesoxynucleotide-Induced Control of
    Schleicher U; Liese J; Justies N; Mischke T; Haeberlein S; Sebald H; Kalinke U; Weiss S; Bogdan C
    Front Immunol; 2018; 9():79. PubMed ID: 29459858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs.
    Diamond JM; Vanpouille-Box C; Spada S; Rudqvist NP; Chapman JR; Ueberheide BM; Pilones KA; Sarfraz Y; Formenti SC; Demaria S
    Cancer Immunol Res; 2018 Aug; 6(8):910-920. PubMed ID: 29907693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses.
    Hossain F; Majumder S; Ucar DA; Rodriguez PC; Golde TE; Minter LM; Osborne BA; Miele L
    Front Immunol; 2018; 9():1288. PubMed ID: 29915603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The host STING pathway at the interface of cancer and immunity.
    Corrales L; McWhirter SM; Dubensky TW; Gajewski TF
    J Clin Invest; 2016 Jul; 126(7):2404-11. PubMed ID: 27367184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation.
    Bald T; Landsberg J; Lopez-Ramos D; Renn M; Glodde N; Jansen P; Gaffal E; Steitz J; Tolba R; Kalinke U; Limmer A; Jönsson G; Hölzel M; Tüting T
    Cancer Discov; 2014 Jun; 4(6):674-87. PubMed ID: 24589924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generation of mouse pluripotent stem cell-derived proliferating myeloid cells as an unlimited source of functional antigen-presenting cells.
    Zhang R; Liu TY; Senju S; Haruta M; Hirosawa N; Suzuki M; Tatsumi M; Ueda N; Maki H; Nakatsuka R; Matsuoka Y; Sasaki Y; Tsuzuki S; Nakanishi H; Araki R; Abe M; Akatsuka Y; Sakamoto Y; Sonoda Y; Nishimura Y; Kuzushima K; Uemura Y
    Cancer Immunol Res; 2015 Jun; 3(6):668-77. PubMed ID: 25672396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments.
    Cauwels A; Van Lint S; Paul F; Garcin G; De Koker S; Van Parys A; Wueest T; Gerlo S; Van der Heyden J; Bordat Y; Catteeuw D; Rogge E; Verhee A; Vandekerckhove B; Kley N; Uzé G; Tavernier J
    Cancer Res; 2018 Jan; 78(2):463-474. PubMed ID: 29187401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis.
    Hensbergen PJ; Wijnands PG; Schreurs MW; Scheper RJ; Willemze R; Tensen CP
    J Immunother; 2005; 28(4):343-51. PubMed ID: 16000952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models.
    Lu Z; Zuo B; Jing R; Gao X; Rao Q; Liu Z; Qi H; Guo H; Yin H
    J Hepatol; 2017 Oct; 67(4):739-748. PubMed ID: 28549917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis.
    Wenzel J; Schmidt R; Proelss J; Zahn S; Bieber T; Tüting T
    Clin Exp Dermatol; 2006 Jul; 31(4):576-82. PubMed ID: 16716166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Naturally produced type I IFNs enhance human myeloid dendritic cell maturation and IL-12p70 production and mediate elevated effector functions in innate and adaptive immune cells.
    Sköld AE; Mathan TSM; van Beek JJP; Flórez-Grau G; van den Beukel MD; Sittig SP; Wimmers F; Bakdash G; Schreibelt G; de Vries IJM
    Cancer Immunol Immunother; 2018 Sep; 67(9):1425-1436. PubMed ID: 30019146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of type I interferon in inducing a protective immune response: perspectives for clinical applications.
    Rizza P; Moretti F; Capone I; Belardelli F
    Cytokine Growth Factor Rev; 2015 Apr; 26(2):195-201. PubMed ID: 25466627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Type I Interferon Released by Myeloid Dendritic Cells Reversibly Impairs Cytomegalovirus Replication by Inhibiting Immediate Early Gene Expression.
    Holzki JK; Dağ F; Dekhtiarenko I; Rand U; Casalegno-Garduño R; Trittel S; May T; Riese P; Čičin-Šain L
    J Virol; 2015 Oct; 89(19):9886-95. PubMed ID: 26202227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines.
    Okada H; Tsugawa T; Sato H; Kuwashima N; Gambotto A; Okada K; Dusak JE; Fellows-Mayle WK; Papworth GD; Watkins SC; Chambers WH; Potter DM; Storkus WJ; Pollack IF
    Cancer Res; 2004 Aug; 64(16):5830-8. PubMed ID: 15313927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IRF-7 is the master regulator of type-I interferon-dependent immune responses.
    Honda K; Yanai H; Negishi H; Asagiri M; Sato M; Mizutani T; Shimada N; Ohba Y; Takaoka A; Yoshida N; Taniguchi T
    Nature; 2005 Apr; 434(7034):772-7. PubMed ID: 15800576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. STING licensing of type I dendritic cells potentiates antitumor immunity.
    Wang J; Li S; Wang M; Wang X; Chen S; Sun Z; Ren X; Huang G; Sumer BD; Yan N; Fu YX; Gao J
    Sci Immunol; 2024 Feb; 9(92):eadj3945. PubMed ID: 38363830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.
    Wei J; Waithman J; Lata R; Mifsud NA; Cebon J; Kay T; Smyth MJ; Sadler AJ; Chen W
    J Immunol; 2010 Nov; 185(10):6013-22. PubMed ID: 20956347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD73 Blockade Promotes Dendritic Cell Infiltration of Irradiated Tumors and Tumor Rejection.
    Wennerberg E; Spada S; Rudqvist NP; Lhuillier C; Gruber S; Chen Q; Zhang F; Zhou XK; Gross SS; Formenti SC; Demaria S
    Cancer Immunol Res; 2020 Apr; 8(4):465-478. PubMed ID: 32047024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.